Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 282-287

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 4, 2012-04 ,pp. : 228-234

Karger

Access to resources Recommend Favorite

BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia

By Jönsson Sofia   Olsson Bob   Jacobsson Stefan   Palmqvist Lars   Ricksten Anne   Ekeland-Sjöberg Kerstin   Wadenvik Hans  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 71, Iss. 1, 2011-02 ,pp. : 7-11

Informa Healthcare

Access to resources Recommend Favorite

Hyperdiploidy Associated with a High BCR-ABL Transcript Level May Identify Patients at Risk of Progression in Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 7-9

Karger

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite